Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore

News

Stay up to date on the latest crypto trends with our expert, in-depth coverage.

banner
All
Crypto
Stocks
Commodities & Forex
Macro
Flash
12:15
Bernstein: The Strength of Data Center REITs Is Underestimated by Indicators
According to Odaily, Bernstein analysts stated in a research report that the strength of data center real estate investment trusts (REITs) is often underestimated. This is because traditional valuation metrics often fail to reflect the long-term value of capital-intensive assets designed to generate cash flow over decades. Adjusted operating cash flow and development return rates, two sector-specific indicators, can more accurately assess this segment’s growth potential. While maintaining shareholder distributions, this sector is able to reinvest funds to expand data center computing power, which is a key advantage. Overall, Bernstein remains optimistic about the outlook for data center REITs. (Golden Ten Data)
12:13
SecondFi: Final Balance Snapshot Completed, Asset Redistribution Expected to Start in Approximately Two Weeks
BlockBeats News, June 26th, SecondFi Update on Incident Funds Recovery Progress: The final balance snapshot was taken on June 26th as an accurate record for the subsequent asset recovery. The engineering and security teams have completed balance verification and recovery mechanism evaluation. It is expected that asset returns will begin in approximately two weeks, with about one week for the implementation of the solution and another week for testing and review, with the specific timeline subject to adjustment based on progress. SecondFi has stated that it will resume operations after confirming the platform's security and completing all security reviews. Currently, users only need to submit an application via a support ticket and are not required to take any other actions.
12:12
Replimune Group Inc. announced that the U.S. Food and Drug Administration (FDA) has officially accepted its resubmitted Biologics License Application (BLA) for the investigational therapy RP1 for the treatment of advanced melanoma.
This acceptance marks a critical step for the company in advancing the marketing process of this oncolytic virus immunotherapy. The FDA has set the Prescription Drug User Fee Act (PDUFA) target review date as December 25, 2024. The submission of this BLA is primarily based on key CERPASS clinical trial data, which evaluated the efficacy and safety of combining RP1 with the anti-PD-1 therapy librolizumab compared to using librolizumab alone in patients with advanced melanoma.
News